Triethylene Glycol

Triethylene Glycol

SCHEMBL1434840

CCc1cc(C(C)C(=O)O)cc(C(C)(C)C)c1O.CCc1cc(C(C)C(=O)O)cc(C(C)(C)C)c1O.OCCOCCOCCO

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 1/20 0.41
HSPA5 P11021 2/20 0.37
AKR1C3 P42330 5/20 0.34
AKR1C2 P52895 5/20 0.34
GLRA3 O75311 1/20 0.34
GLRB P48167 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
ADRB2 P07550 1/20 0.33
ADRB3 P13945 1/20 0.33
LMNA P02545 1/20 0.33
RECQL P46063 1/20 0.33
VCAM1 P19320 1/20 0.32
PTGS2 P35354 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
CYP3A4 P08684 1/20 0.32
TSHR P16473 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HIF1A Q16665 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triethylene Glycol SCHEMBL10455917 0.86 CYP1A2 (0.39) CYP1A2CYP2D6AKR1C3AKR1C2GLRA3
Triethylene Glycol SCHEMBL379325 0.86 CYP1A2 (0.39) CYP1A2CYP2D6AKR1C3AKR1C2GLRA3
SCHEMBL1434835 0.84 CYP1A2 (0.44) CYP1A2CYP2D6HSPA5GLRA3GLRB
SCHEMBL27435097 0.78 CYP1A2 (0.48) CYP1A2CYP2D6HSPA5AKR1C3AKR1C2
SCHEMBL100584 0.77 GLRA3 (0.50) CYP1A2CYP2D6AKR1C3AKR1C2GLRA3
SCHEMBL6275312 0.77 GLRA3 (0.50) CYP1A2CYP2D6AKR1C3AKR1C2GLRA3
1,6-Hexanediol SCHEMBL27465667 0.76 VCAM1 (0.43) CYP1A2CYP2D6AKR1C3AKR1C2GLRA3
1,6-Hexanediol SCHEMBL887987 0.76 VCAM1 (0.43) CYP1A2CYP2D6AKR1C3AKR1C2GLRA3
Propionic Acid SCHEMBL30185774 0.76 GPR55 (0.44) CYP1A2CYP2D6AKR1C3AKR1C2GLRA3
Triethylene Glycol SCHEMBL8819163 0.76 HSPA5 (0.46) HSPA5LMNAVCAM1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1411084-B1 ANTIBACTERIAL COMPOSITION FOR MEDICAL TOOL ADEKA CORP (JP) 2011-03-30 EP disclosed
US-7279509-B2 Antibacterial composition for medical tool ADEKA CORPORATION (JP) 2007-10-09 US disclosed
US-20040166163-A1 Antibacterial composition for medical tool ADEKA CORPORATION (JP) 2004-08-26 US disclosed
EP-1411084-A1 ANTIBACTERIAL COMPOSITION FOR MEDICAL TOOL ASAHI DENKA KOGYO KABUSHIKI KAISHA (JP) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040166163-A1 Antibacterial composition for medical tool NLRP3, NLRP1, MRPL37 CYP1A2 3570/4885CYP2D6 3109/4885HSPA5 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.